JP Morgan Cazenove Reiterates GSK (GLAXF) Underweight Recommendation

JP Morgan Cazenove reiterated an 'Underweight' recommendation for GSK (OTCPK:GLAXF) on November 7, 2025, despite an average one-year analyst price target of $22.01, which suggests a 7.96% upside from its $20.39 closing price. The company projects annual revenue of 32,186MM and non-GAAP EPS of 1.58. Institutional sentiment shows a nuanced picture, with a slight decrease in the number of reporting funds but a 2.89% increase in total shares owned by institutions, alongside an 8.34% rise in the average portfolio weight dedicated to GSK.

Analysis

JP Morgan Cazenove reiterated an "Underweight" recommendation for GSK (OTCPK:GLAXF) on November 7, 2025, signaling a cautious outlook for the pharmaceutical company. This rating contrasts with the average one-year analyst price target of $22.01, which implies a 7.96% upside from the current $20.39 closing price, though the wide target range from $15.05 to $35.21 highlights significant divergence in analyst expectations.

The company's projected annual revenue growth is notably subdued at just 0.06%, reaching 32,186MM, alongside a projected non-GAAP EPS of 1.58. This minimal revenue expansion suggests limited organic growth drivers in the near term, potentially underpinning the "Underweight" rating despite the positive average price target.

Institutional sentiment presents a mixed picture; while total shares owned by institutions increased by 2.89% and average portfolio weight rose by 8.34%, the number of reporting funds decreased by 0.42%. Furthermore, several major institutional holders, including Vanguard Total International Stock Index Fund (VGTSX) and iShares Core MSCI EAFE ETF (IEFA), notably decreased their portfolio allocation to GSK by 10.90% and 11.16% respectively, indicating a reduction in conviction despite some increasing absolute share counts.

Key Decisions for Investors

• Carefully consider JP Morgan Cazenove's "Underweight" recommendation, which signals potential underperformance despite the average price target upside.
• Scrutinize GSK's long-term growth drivers given the minimal projected annual revenue increase of 0.06%.
• Monitor institutional positioning closely, as several large funds have reduced their portfolio allocation to GSK, indicating waning conviction.
• Evaluate the divergence between the average analyst price target and the "Underweight" rating, recognizing the wide range of analyst expectations.